Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

Calendar

05:30pm Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
28/07/26	$13.95	+1.01%	65,665
27/07/26	$13.81	+1.92%	52,787
24/07/26	$13.55	-0.37%	54,940
23/07/26	$13.60	-0.80%	42,099
22/07/26	$13.71	-1.58%	46,762

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

13.95USD

Average target price

12.00USD

Spread / Average Target

-13.98%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 00:00:00 29/07/2026 +04			5-day change	1st Jan Change
13.95 ^USD	+1.01%		+0.14%	-0.04%

07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
07-01	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI

Market Cap	293M 257M 239M 220M 412M 27.95B 419M 2.84B 1.11B 13.86B 1.1B 1.07B 47.88B	P/E 2026 *	-465x	P/E 2027 *	-698x
Enterprise Value	119M 104M 96.97M 89.19M 167M 11.34B 170M 1.15B 450M 5.62B 445M 436M 19.42B	EV / Sales 2026 *	0.67x	EV / Sales 2027 *	0.66x
Free-Float	89.38%	Yield 2026 *	-	Yield 2027 *	-

07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
07-01	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
06-29	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
06-23	Top cases on the US Supreme Court's docket	RE
06-22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
06-18	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
06-09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
06-05	The Jobs Report Just Made the Fed's Life Harder
06-05	To infinity and beyond
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
06-04	Top cases on the US Supreme Court's docket	RE
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

Amarin Corporation plc Stock

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Valuation: Amarin Corporation plc

Chart: Amarin Corporation plc

Latest news : Amarin Corporation plc

Last Transcript: Amarin Corporation plc

Analysts' recommendations: Amarin Corporation plc

Press Releases: Amarin Corporation plc

News in other languages: Amarin Corporation plc

Quotes and Performance

Course Extremes

Managers and Directors: Amarin Corporation plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03:01pm	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence	AQ
07-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
07-01	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
05-27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ
04-29	Amarin: Q1 Earnings Snapshot	AQ

06-05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
29/07/25	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
24/06/25	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
29/03/22	Amarin reçoit un remboursement pour VAZKEPA® en Suède

1 day	+1.01%
1 week	+0.14%
Current month	-12.48%
1 month	-12.32%
3 months	-0.07%
6 months	-7.43%
Current year	-0.04%

1 week	13.47	14.34
1 month	13.47	16.79
Current year	12.96	17.31
1 year	12.96	20.9
3 years	7.08	27.4
5 years	7.08	119.4
10 years	7.08	522.4

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	04/06/2024
Peter Fishman DFI	Director of Finance/CFO	42	23/10/2024
Jonathan Provoost CMP	Compliance Officer	56	15/11/2023

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	04/06/2024
Patrice Bonfiglio BRD	Director/Board Member	43	28/02/2023
Keith Horn BRD	Director/Board Member	67	28/02/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/07/26	Peter Fishman	Fiscal year	Chief Financial Officer	6,100	0.0015%
01/07/26	Steven Ketchum	Fiscal year	Chief Technology Officer	9,263	0.0022%
01/07/26	David Keenan	Fiscal year	Chief Operating Officer	9,302	0.0022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARIN CORPORATION PLC	+1.01%	+0.14%	-6.94%	-41.39%	293M
ARGENX SE	+0.18%	+2.11%	+50.54%	+69.45%	55.01B
WUXI APPTEC CO., LTD.	-1.32%	-2.71%	+34.27%	+77.57%	54.24B
BIONTECH SE	+1.49%	+0.13%	-18.03%	-13.94%	23.38B
INSMED INCORPORATED	-0.57%	-4.13%	+2.34%	+387.73%	22.57B
WUXI BIOLOGICS (CAYMAN) INC.	+2.07%	+1.39%	+17.20%	-10.70%	20.19B
GENMAB A/S	-0.24%	-0.50%	+29.62%	-31.77%	17.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.14%	-3.75%	+26.23%	+558.64%	15.5B
PHARMAESSENTIA CORPORATION	-6.69%	-5.11%	+169.13%	+304.89%	14.2B
EXELIXIS, INC.	+1.25%	+0.69%	+27.30%	+184.69%	14.2B
Average	-0.48%	-0.58%	+33.17%	+148.52%	23.74B
Weighted average by Cap.	-0.44%	-0.52%	+35.13%	+131.69%

	2026 *	2027 *
Net sales	178M 156M 145M 134M 251M 16.99B 255M 1.72B 675M 8.42B 667M 653M 29.1B	159M 139M 130M 119M 224M 15.17B 228M 1.54B 603M 7.53B 596M 583M 26B
Net income	-12.75M -11.19M -10.42M -9.58M -17.96M -1.22B -18.27M -124M -48.37M -604M -47.85M -46.82M -2.09B	-9.04M -7.93M -7.39M -6.79M -12.73M -863M -12.95M -87.63M -34.3M -428M -33.93M -33.2M -1.48B
Net Debt	-174M -153M -142M -131M -245M -16.61B -249M -1.69B -660M -8.24B -653M -639M -28.46B	-187M -165M -153M -141M -264M -17.91B -269M -1.82B -711M -8.88B -704M -689M -30.69B